Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status

By afschroeder • October 25, 2025

Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries MJ, Zhang P, Rivera VM, Gettinger S. Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer. 2025 Nov;26(7):e503-e513.e11. doi: 10.1016/j.cllc.2025.05.016. Epub 2025 Jun 6. PMID: 40582920.

Tags: ALK inhibitors, Cedars Sinai DoM, circulating tumor DNA, G1202R, Hematology/Oncology, Publications, Resistance mutations, Tumor biopsy

Artificial Intelligence-derived Measurements of Myosteatosis from Coronary Artery Calcium CT Scans to Predict COPD: The Multi-Ethnic Study of Atherosclerosis

Azimi A, Atlas K, Reeves AP, Zhang C, Wasserthal J, Mirjalili SR, Atlas T, Henschke CI, Yankelevitz DF, Zulueta JJ, de-Torres JP, Seijo LM, Mechanick[...]

End-of-Life Care Processes and Outcomes for Older Adults Treated by International Medical Graduates vs. US Medical Graduates

Kaneshiro GS, Reuben DB, Zingmond DS, Walling AM, Jena AB, Wenger NS, Damberg CL, Xu H, Gross N, Gotanda H, Tsugawa Y. End-of-Life Care Processes[...]

Evaluating Translational AI: A Two-Way Moving Target Problem

Leuchter RK, Turner WB, Ouyang D. Evaluating Translational AI: A Two-Way Moving Target Problem. NEJM AI. 2025 Dec;2(12):10.1056/aip2500705. doi: 10.1056/aip2500705. Epub 2025 Nov 14. PMID:[...]